Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dominion Energy Inc (D) vs Mesoblast Limited (MESO) Price & Performance

Dominion Energy IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Dominion Energy Inc vs Mesoblast Limited — how do they compare? Dominion Energy Inc trades at $68.36 (market cap $59.06B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Dominion Energy Inc is far larger — about 27.3× Mesoblast Limited's market cap, and Dominion Energy Inc pays a 3.98% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

DMESO
Market Cap
$59.06B$2.16B
Sector
UtilitiesTechnology
52-Week High
$71.67$20.96
52-Week Low
$57.08$12.88
Enterprise Value
$113.18B$2.17B
Dividend Yield
3.98%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dominion Energy Inc

No Aura AI signal available yet.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About Dominion Energy Inc

Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.

Read more on D

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO